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Case Report
Introduction
Polymyxins B (PMB) and E (colistimethate sodium, colistin 
[CMS]) exert a bactericidal effect on the gram-negative bacte-
rial cell wall, causing permeability changes in the cytoplasmic 
membrane, leading to cell death. They were introduced into 
medical practice in the 1950s but their use was substantially 
decreased from the 1970s to 2000s due to significant nephro-
toxicity and neurotoxicity compared to the newly introduced 
antibiotics. The increasing prevalence of multidrug-resistant 
gram-negative bacteria infections in this century has led to an 
upsurge in the use of these “older” drugs. Reports of poten-
tially severe and life-threatening respiratory paralysis caused 
by neuromuscular blockage associated with their use have 
been published, mostly in the 1960s to 1970s.1,2 Reports also 
suggested that polymyxin-related neuromuscular blockade 
might be enhanced by the presence of other drugs with similar 
toxicities such as neomycin,3 anesthetics,4 and neuromuscular 
blocking agents,5 including pipecuronium.6 We report a case 
with episodes of both CMS and subsequent PMB-induced 
apnea in a patient receiving “muscle relaxants.”
Case Report
A 57-year-old male with history of diabetes mellitus, atrial 
fibrillation, and degenerative joint disease underwent a left 
L4-L5 hemilaminectomy, medial facetectomy, and micro-
diskectomy to relieve the symptoms of spinal stenosis. 
The surgery was complicated by a methicillin-sensitive 
Staphylococcus aureus (MSSA) bacteremia. A surface culture 
of the open surgical site grew MSSA, Candida albicans, and 
multidrug resistant Pseudomonas aeruginosa (resistant to 
levofloxacin; minimum inhibitory concentration [MIC] >16 
µg/mL), intermediate susceptibility to cefepime (MIC = 8 µg/
mL) and piperacillin/tazobactam (MIC = 32 µg/mL), but sen-
sitive to meropenem (MIC <1 µg/mL). A surveillance culture 
1 month prior to this wound infection did not grow a multi-
drug-resistant Pseudomonas aeruginosa. He was discharged 
to a nursing home to receive intravenous (IV) meropenem 1 g 
every 8 hours and oral fluconazole 400 mg daily. He was also 
prescribed the muscle relaxant cyclobenzaprine (Flexeril) 
10 mg 3 times a day as needed for muscle spasm. One week later, 
cyclobenzaprine was changed to tizanidine (Zanaflex) 1 mg 
at bedtime. Two weeks later, when Pseudomonas aeruginosa 
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resistant to meropenem (MIC = 8) was recovered from an 
open wound with a purulent discharge, IV CMS was started at 
3 mg/kg/day divided into 2 doses, and the dose of IV merope-
nem was increased to 2 g every 8 hours. CMS was chosen 
rather than an aminoglycoside as his infectious disease physi-
cian believed this offered the patient the best chance to receive 
a possible synergic combination to treat the multiresistant 
Pseudomonas.7 After completing the 3 weeks of IV CMS, and 
5 weeks of meropenem and fluconazole, he was discharged 
from the nursing home. His tizanidine dose was increased to 4 
mg every 8 hours 2 weeks later. He received 3 additional 
weeks of IV CMS and IV meropenem at home (Figure 1). 
During this time he became progressively weak with frequent 
falls and also became short of breath. During the third week at 
home, he stopped talking, could not move his arms, and had 
labored respirations. He was intubated when seen as an emer-
gency and brought to a hospital. His serum electrolytes and 
renal function tests are shown in Table 1. His serum creatinine 
had risen from 0.6 mg/dL prior to CMS to 1.1 mg/dL. A creati-
nine clearance was 110 mL/min at this admission. Computed 
tomography (CT) showed no intracranial lesions. A CT angi-
ography of the head and neck showed no significant stenosis. 
He was given tissue plasminogen activator for the treatment of 
a probable ischemic stroke. Tizanidine and CMS were discon-
tinued and PMB started with a loading dose of 160 mg IV 
followed by 100 mg every 12 hours. IV meropenem and oral 
fluconazole were also restarted. He was extubated 1 day after 
the admission.
On the fourth day after admission (and no longer receiv-
ing a muscle relaxant), he developed slurred speech, inability 
to move both his upper extremities, and apnea 10 minutes 
after completion of an infusion of PMB. He was intubated 
again. A CT scan of his head did not show changes, and his 
electroencephalogram was within normal limits. His antibi-
otics were discontinued (Figure 1). Three days later he was 
extubated as his right upper extremity weakness had 
improved. It was noted that his peripheral eosinophil count 
had increased to 7% after 4 weeks of meropenem and fluco-
nazole and 2 weeks of CMS, and then to 11% 2 weeks later. 
It was 19% at the time when all antibiotics were stopped. 
One month later it had fallen to 10%. The patient was not 
restarted on any antibiotics. The wound was treated with wet 
to dry dressing changes and debrided 5 months later. The 
patient remains with a chronic nonhealing wound.
Figure 1. Time Line of Antibiotics and muscle relaxants.
Table 1. Laboratory Results Before, on the Day of Admission, and on the Third Day of Admission.
Labs Normal Range
Prior to Starting 
Colistin
2 Weeks After 
Colistin
5 Weeks 
After Colistin
6 Weeks After 
Colistin (on the 
Date of Admission)
Third Day of 
Admission
Potassium 3.7-4.8 mmol/L 4.5 4.5 3.9 3.0 3.5
Magnesium 1.9-2.4 mg/dL NA 1.5 1.7 0.9 1.5
Calcium 8.9-10.2 mg/dL 8.4 9.2 9.5 9.3 8.8
Corrected calcium 8.9-10.2 mg/dL 10.0 10.7 10.7 10.8 NA
Albumin 3.3-4.6 g/dL 2.0 2.1 2.5 2.1 NA
Creatinine 0.8-1.3 mg/dL 0.62 1.11 1.17 1.09 0.99
White blood cell 3.7-10.3 k/µL 8.0 6.1 9.5 8.7 8.7
C-reactive protein 0-0.9 mg/dL 5.4 2.1 5.4 NA 10.4
Abbreviation: NA, not available.
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Discussion
Polymyxins B and E are small basic peptides (molecular 
weight ~ 1000) and cationic detergents that exert a bacteri-
cidal effect on the gram-negative bacterial cell wall, causing 
permeability changes in the cytoplasmic membrane, leading 
to cell death.1,8 Their use was substantially decreased in clini-
cal practice from the 1970s to 2000s due to their significant 
nephrotoxicity and neurotoxicity compared to the “newly” 
introduced antibiotics.9 The increasing prevalence of multi-
drug-resistant gram-negative bacteria infections in this cen-
tury has led to an upsurge in the use of PMB and CMS.
Respiratory muscle paralysis is a rare but potentially fatal 
complication of the use of PMB and CMS.2 The incidence of 
CMS associated neurotoxicity reported in the literature prior to 
1975 ranged from 7.3% to 27%, with paresthesia constituting 
most of the reports.1,10 Lindesmith et al2 described 21 cases of 
reversible respiratory paralysis in 1968; 15 cases were associ-
ated with CMS and 6 cases with PMB therapy. The number of 
doses associated with episodes of respiratory arrest ranged 
from a single dose to 45 doses of antibiotics. Onset of paralysis 
occurred from 1 to 26 hours after a dose of PMB or CMS. Most 
of those cases were described in patients with renal disease,2 
suggesting that the risk of polymyxin-associated neuromuscu-
lar blockade is increased with impaired renal function.
Other neurotoxic effects include circumoral paresthesia 
or numbness, tingling or formication of the extremities, gen-
eralized pruritus, vertigo, dizziness, and slurring of 
speech.1,2,9 Untreated neurotoxicity associated with PMB or 
CMS is a precipitating factor for respiratory muscle paralysis 
and respiratory failure.
The proposed mechanism of CMS neurotoxicity is a non-
competitive myoneuronal presynaptic blockade of acetyl-
choline release that may be enhanced by hypocalcemia-induced 
prolongation of depolarization.9 Concomitant drug therapies 
including other neurotoxic drugs (anesthetics, aminoglyco-
sides, and paralytics), corticosteroids, narcotics, and muscle 
relaxants (which were given to this patient) probably increase 
the risk of CMS neurotoxicity.1,9
After the resurgence in the use of CMS and PMB for mul-
tidrug-resistant gram-negative bacteria in this century, there 
Table 2. Case Reports Summary of Colistin/Polymyxin-Induced Apnea That Required Intubation, Published After 2010.
No. Study Age Gender Indication
IV Drug and 
Dose
Duration of 
Antibiotic 
Administration 
Prior to Onset of 
Apnea
Duration of 
Endotracheal 
Intubation, 
Outcome
Associated 
With 
Underlying 
Renal Disease
Concomitant 
Neurotoxic Drugs
1 Wahby et al11 
(2010)
33 Female MDR Acinetobacter 
baumannii
170 mg of 
colistin base 
activity every 
12 h
5 days 5 days, 
survived
NA Methylprednisolone, 
hydromorphone
2 Spapen et al12 
(2011)
51 Male New Delhi 
metallo-β-
lactamase-1 
Escherichia coli
Colistin 3 million 
units every 8 h
19 days NA, died No Anesthetic agent
3 Wunsch et al,13 
case 1 (2012)
48 Male Carbapenem 
resistant 
Klebsiella 
pneumoniae
Polymyxin 125 
mg every 12 h
1 hour NA No IV amikacin
4 Wunsch et al,13 
case 2 (2012)
58 Male MDR Klebsiella 
pneumoniae
Polymyxin B 80 
mg every 12 h
2 days 1 day Yes NA
 Second test 
dose of IV 
polymyxin
2 hours 1 day, survived  
5 Fernandez  
et al14 (2013)
75 Male MDR Pseudomonas 
aeruginosa
Colistin 3 million 
international 
units every 8 h
36 hours 1 day, died No NA
6 Wadia and 
Tran15 (2014)
51 Male Acinetobacter 
baumannii, ESBL 
Proetus mirabilis
Colistin 275 mg 
q12h
8 days NA, survived No NA
7 Shrestha et al16 
(2014)
31 Female Pan resistant 
Pseudomonas
Colistin 200 mg 
q12h
3 days 1 day, survived Yes NA
8 Nigam et al17 
(2015)
20 Female MDR Pseudomonas Colistin 1 million 
units q8h
5 days No intubation, 
survived
NA No
9 Our patient 57 Male MDR Pseudomonas 
aeruginosa
Colistin 120 
mg IV q12h; 
polymyxin B 
100 mg IV q12
6 weeks, and again 
for only 3 days
3 days twice, 
survived
No Tizanidine
Abbreviations: MDR, multidrug-resistant; NA, not available; IV, intravenous.
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have been several case reports of PMB- or CMS-related 
respiratory apnea that required intubation.11-17 Seven of 9 
cases were associated with CMS (Table 2).
Our patient received intravenous CMS 3 mg/kg/day 
divided into 2 doses for 6 weeks. He did not appear to have 
underlying renal insufficiency prior to admission, and his cre-
atinine clearance was never below 95 mL/min during his hos-
pital stay. His serum calcium was within normal limits. He 
did not have tetany, arrhythmia, seizure, or involuntary move-
ments although he was slightly hypokalemic and hypomagne-
semic. He developed shortness of breath after a prolonged 
course of IV CMS and apnea after 3 days of PMB. He devel-
oped eosinophilia but did not have a rash or organ injury. 
Stool parasite studies were negative as was serum antibody 
for Strongyloides stercoralis. Eosinophilia associated with 
CMS or PMB has been reported in 1.6% of patients receiving 
these drugs.1 Our patient’s eosinophilia could have resulted 
from exposure to one or more of medications that included 
meropenem, fluconazole, tizanidine, CMS, and PMB.
Neurological diseases such as stroke and seizure were 
excluded in this patient. He was not receiving any steroids. 
His respiratory paralysis reversed after stopping PMB and 
CMS.
The patient received the muscle relaxants cyclobenzap-
rine (Flexeril) and tizanidine (Zanaflex), which could have 
potentially increased neuromuscular blockage leading to his 
first episode of respiratory muscle paralysis, though this 
interaction has not been reported.9 The dose of tizanidine, 4 
mg every 8 hours, was also relatively high. He did not receive 
concurrent curariform muscle relaxants or other neurotoxic 
drugs (tubocurarine, succinylcholine, gallamine, decameth-
nium, and sodium citrate), which have been associated with 
respiratory depression.1 The patient’s CMS- and PMB-
induced apnea might have been enhanced by the muscle 
relaxants. His Naranjo adverse drug reaction probability 
scale of 7 indicates these event were probably an adverse 
drug reaction.18
With an increasing use of IV CMS and PMB to treat multi-
drug-resistant gram-negative bacteria infections, clinicians 
must be aware of respiratory muscle paralysis as a rare and 
potentially fatal side effect of these drugs. Patients receiving 
these drugs should have regular reviews for drug-drug interac-
tions, as well as renal and neurological assessments.11 If the 
patient develops neurotoxicity, CMS or PMB should be 
stopped. There is no role for reversal agents such as neostig-
mine, although calcium infusions and antihistamines have been 
suggested to have some benefit in reversing the paralysis.2 As 
this reaction can be reversible, continuous renal replacement 
therapy or hemodialysis seems a reasonable option to help in 
patients with acute renal failure or with high serum levels of 
polymyxins.
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